Ascentage Pharma’s proprietary novel drugs, lisaftoclax & olverembatinib included in Chinese Society of Clinical Oncology 2025 Guidelines: Rockville, Maryland Wednesday, April 2 ...

Ascentage Pharma Group Corp. Ltd. said two of its novel candidates have been included in the 2025 Chinese Society of Clinical Oncology Guidelines, including its in-house developed Bcl-2 selective ...

This is the first CSCO Guidelines recommendation for lisaftoclax (APG-2575), making it the only China-developed Bcl-2 ...

Ascentage Pharma (AAPG) announced that two of its proprietary novel drugs have been included in the 2025 Chinese Society of Clinical Oncology, ...

US drug maker AbbVie has launched its key leukemia drug, Venetoclax, in India, marking its entry into the country's oncology ...